Canada· CA-DIN-02438801
ZYDELIG
A idelalisib product containing idelalisib, registered in Canada by GILEAD SCIENCES CANADA INC. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Idelalisib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EM01 (idelalisib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Idelalisib · ATC L01EM01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of idelalisib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Idelalisib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$222.92
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- IDELALISIB
- Manufacturer
- GILEAD SCIENCES CANADA INC
- Country
- Canada (CA)
- ATC code
- L01EM01
- ATC class
- Idelalisib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
820 interactions on record for idelalisib.
Graded by severity as the source publishes them — 236 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Idelalisib · interactions on record
820 records
- 236 severe
- 568 moderate
- 16 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- LoperamideA07DA03severe
- BudesonideA07EA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Idelalisib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomZydelig 150mg tabletsGilead Sciences Ltd
- United StatesZydeligGilead Sciences, Inc.
- FinlandZydeligGilead Sciences Ireland UC
- CzechiaZYDELIGGilead Sciences Ireland UC, Carrigtohill
- SpainZydelig 100 mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FranceZYDELIG 100 mg, comprimé pelliculéGILEAD SCIENCES IRELAND UC (IRLANDE)
- BelgiumZydelig 100 mgGilead Sciences Ireland UC
- IrelandZydelig 100 mg film-coated tabletsGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zydelig
- Liechtenstein · Zydelig
- Norway · Zydelig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df0626da-799d-41af-aa70-ecc66414d81f GET /v1/drugs/df0626da-799d-41af-aa70-ecc66414d81f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02438801",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EM01",
"schedule": [
"Prescription"
],
"drug_code": "92319",
"strengths": [
"150 MG"
],
"ahfs_class": null,
"substances": [
"IDELALISIB"
],
"product_categorization": null
}See everything about idelalisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.